A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
This Was Not a Budget for an Aspiration Nation
21 March 2013
Budget day provided an opportunity for the Chancellor to lay out a visionary, comprehensive and, above all, ambitious plan to restore the British economy to health. Sadly we didn't get it, says Professor Stephen Caddick (UCL Enterprise).
Read the full article at www.huffingtonpost.co.uk